Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. | Century Therapeutics has joined ...

Building on its autologous CD19 CAR-T cell therapy obe-cel, Autolus added a CD22 CAR to create AUTO1/22. The dual mechanism is intended to address a major cause of treatment failure. Thursday ...

Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results for the year 2024. This move aims to focus on potentially groundbreaking ...

which it had designed to target three proteins — CD19, CD20 and CD22. Now, it’s shelving those too, despite having received a green light from regulators to proceed with human testing of CRG-023.

Other ADCs directed against other B-cell lineage antigens, including CD22, CD19 and CD70, are currently in Phase I/Phase II clinical trials. Early clinical data are encouraging. Important ...

March 05, 2025--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T ...